Dr Reddys Laboratories Ltd

Dr Reddy's Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Dr Reddys Laboratories Ltd

₹ 1,304 -1.18%
29 May - close price
drreddys.com BSE: 500124 NSE: DRREDDY
About

Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.

Key Points

Market Leadership: # https://www.bseindia.com/xml-data/corpfiling/AttachHis/95588392-8071-413a-9d78-991bd1d87d4a.pdf#page=13 #}
The company is a player in the Indian Pharmaceutical Market (IPM), ranked No. 10, with strong therapy leadership, including the #1 position in stemmatological and #2 in vaccines. It also has 15 brands featured among the IPM Top 300.

Website BSE NSE
  • Market Cap ₹ 1,08,798 Cr.
  • Current Price ₹ 1,304
  • High / Low ₹ 1,380 / 1,148
  • Stock P/E 33.8
  • Book Value ₹ 376
  • Dividend Yield 0.61 %
  • ROCE 12.7 %
  • ROE 10.7 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • The company has delivered a poor sales growth of 8.99% over past five years.
  • Earnings include an other income of Rs.1,690 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of Nifty 50 BSE 500 BSE Healthcare BSE 100 BSE 200

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
4,554 5,437 4,839 4,103 5,105 5,841 6,696 5,015 5,563 7,810 4,619 4,283 3,822
3,493 3,210 3,210 3,447 3,726 3,888 3,975 3,823 4,120 3,972 4,138 4,183 4,322
Operating Profit 1,061 2,228 1,629 656 1,379 1,953 2,722 1,192 1,443 3,837 480 100 -500
OPM % 23% 41% 34% 16% 27% 33% 41% 24% 26% 49% 10% 2% -13%
115 234 223 228 213 218 208 235 414 398 364 360 567
Interest 3 4 6 6 6 7 28 43 31 19 33 41 54
Depreciation 237 237 246 246 246 250 260 265 264 280 295 314 318
Profit before tax 937 2,220 1,601 632 1,339 1,914 2,641 1,119 1,562 3,936 516 104 -306
Tax % 28% 26% 25% 25% 23% 26% 29% 24% 23% 25% 25% 13% -28%
672 1,639 1,193 475 1,035 1,417 1,882 849 1,201 2,961 387 91 -219
EPS in Rs 8.08 19.69 14.30 5.70 12.41 16.99 22.56 10.18 14.39 35.48 4.64 1.09 -2.63
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
10,011 10,292 9,720 9,359 10,626 11,850 13,349 14,405 16,962 19,484 23,115 20,533
7,608 8,219 7,899 7,990 8,290 8,967 10,212 11,803 12,724 13,557 15,691 16,615
Operating Profit 2,403 2,073 1,820 1,370 2,336 2,883 3,137 2,602 4,238 5,926 7,425 3,917
OPM % 24% 20% 19% 15% 22% 24% 24% 18% 25% 30% 32% 19%
211 317 516 164 202 730 801 474 568 862 961 1,690
Interest 64 64 57 63 57 48 47 38 17 22 110 148
Depreciation 490 650 735 774 781 789 835 814 923 976 1,039 1,207
Profit before tax 2,060 1,677 1,544 697 1,701 2,776 3,056 2,224 3,866 5,791 7,236 4,251
Tax % 18% 18% 10% 19% 25% -6% 28% 27% 32% 25% 26% 24%
1,679 1,374 1,384 567 1,277 2,938 2,186 1,623 2,613 4,342 5,349 3,220
EPS in Rs 19.71 16.11 16.70 6.83 15.38 35.36 26.29 19.51 31.38 52.06 64.11 38.58
Dividend Payout % 20% 25% 24% 59% 26% 14% 19% 31% 26% 15% 12% 21%
Compounded Sales Growth
10 Years: 7%
5 Years: 9%
3 Years: 7%
TTM: -11%
Compounded Profit Growth
10 Years: 9%
5 Years: 12%
3 Years: 7%
TTM: -40%
Stock Price CAGR
10 Years: 8%
5 Years: 4%
3 Years: 12%
1 Year: 4%
Return on Equity
10 Years: 14%
5 Years: 15%
3 Years: 16%
Last Year: 11%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 85 85 83 83 83 83 83 83 83 83 83 84
Reserves 10,549 11,993 11,518 11,725 12,601 15,109 16,900 18,253 20,391 24,157 28,773 31,282
3,126 3,085 2,355 2,589 1,065 1,457 1,214 2,205 51 793 3,493 5,737
2,696 2,422 2,491 2,704 2,499 2,827 3,431 3,954 4,850 5,326 5,941 6,500
Total Liabilities 16,456 17,585 16,447 17,100 16,248 19,476 21,630 24,496 25,375 30,359 38,291 43,602
3,249 4,438 4,842 4,717 4,683 4,434 5,844 6,150 7,195 7,589 8,232 10,730
CWIP 488 616 540 675 400 412 901 1,200 924 1,211 2,197 1,369
Investments 3,862 5,076 3,102 3,636 3,934 5,486 4,649 4,937 7,440 7,321 13,194 15,595
8,856 7,455 7,963 8,072 7,231 9,145 10,235 12,208 9,815 14,239 14,668 15,908
Total Assets 16,456 17,585 16,447 17,100 16,248 19,476 21,630 24,496 25,375 30,359 38,291 43,602

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
1,786 2,747 1,016 1,539 2,762 1,839 3,514 1,339 5,053 3,450 4,225 4,660
-2,031 -1,919 1,430 -1,180 -546 -1,689 -1,454 -1,990 -3,403 -3,429 -5,697 -5,785
189 -693 -2,582 -304 -2,223 -224 -794 506 -2,697 68 1,591 1,117
Net Cash Flow -56 135 -135 54 -8 -74 1,266 -146 -1,047 89 118 -7
Free Cash Flow 832 1,665 33 753 2,197 1,371 2,910 -18 3,506 1,944 1,791 1,846
CFO/OP 94% 152% 74% 125% 128% 80% 126% 70% 138% 80% 78% 143%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 172 138 165 164 128 143 112 125 92 87 94 73
Inventory Days 223 234 256 258 242 224 250 242 219 291 275 268
Days Payable 93 99 110 147 124 109 118 121 127 148 120 103
Cash Conversion Cycle 302 273 311 274 246 257 243 247 184 230 250 239
Working Capital Days 99 82 112 98 125 116 95 89 95 130 63 96
ROCE % 16% 12% 11% 5% 12% 19% 15% 12% 19% 25% 26% 13%

Insights

In beta
Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
R&D Spend as % of Revenue
%

Log in to view insights

Please log in to see hidden values.

Login
ANDA Filings (US)
Number
Pending ANDAs (USFDA)
Number
Global DMF Filings
Number
New Global Product Launches
Number
Global Patient Reach
Million Patients
R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
26.69% 26.66% 26.65% 26.65% 26.65% 26.64% 26.64% 26.64% 26.64% 26.64% 26.64% 26.63%
26.99% 28.19% 28.62% 29.13% 27.68% 27.53% 26.85% 25.75% 25.33% 24.69% 22.34% 21.14%
21.99% 21.04% 18.65% 18.31% 20.72% 21.48% 22.89% 25.63% 26.73% 27.99% 30.44% 30.72%
24.11% 23.93% 25.89% 25.73% 24.78% 24.20% 23.46% 21.69% 21.04% 20.45% 20.33% 21.27%
0.21% 0.18% 0.18% 0.17% 0.17% 0.16% 0.16% 0.29% 0.26% 0.25% 0.25% 0.24%
No. of Shareholders 2,46,7692,43,4452,57,7942,55,5002,67,6943,10,4034,03,6694,59,6054,51,9294,49,2164,55,2434,49,665

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls